Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism.
Annonaceae
Parkinson
cognitive impairment
food toxin
risk factor
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
22
08
2022
received:
04
03
2022
accepted:
25
08
2022
pubmed:
11
10
2022
medline:
21
12
2022
entrez:
10
10
2022
Statut:
ppublish
Résumé
High consumption of Annona muricata fruit has been previously identified as a risk factor for atypical parkinsonism in the French Caribbean islands. We tested whether consumption of Annonaceae products could worsen the clinical phenotype of patients with any form of degenerative parkinsonism. We analyzed neurological data from 180 Caribbean parkinsonian patients and specifically looked for dose effects of lifelong, cumulative Annonaceae consumption on cognitive performance. Using unsupervised clustering, we identified one cluster with mild/moderate symptoms (N = 102) and one with severe symptoms including cognitive impairment (N = 78). We showed that even low cumulative consumption of fruits/juices (>0.2 fruit-years) or any consumption of herbal tea from Annonaceae worsen disease severity and cognitive deficits in degenerative parkinsonism including Parkinson's disease (OR fruits-juices: 3.76 [95% CI: 1.13-15.18]; OR herbal tea: 2.91 [95% CI: 1.34-6.56]). We suggest that more restrictive public health preventive recommendations should be made regarding the consumption of Annonaceae products. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
High consumption of Annona muricata fruit has been previously identified as a risk factor for atypical parkinsonism in the French Caribbean islands.
OBJECTIVE
We tested whether consumption of Annonaceae products could worsen the clinical phenotype of patients with any form of degenerative parkinsonism.
METHODS
We analyzed neurological data from 180 Caribbean parkinsonian patients and specifically looked for dose effects of lifelong, cumulative Annonaceae consumption on cognitive performance. Using unsupervised clustering, we identified one cluster with mild/moderate symptoms (N = 102) and one with severe symptoms including cognitive impairment (N = 78).
RESULTS
We showed that even low cumulative consumption of fruits/juices (>0.2 fruit-years) or any consumption of herbal tea from Annonaceae worsen disease severity and cognitive deficits in degenerative parkinsonism including Parkinson's disease (OR fruits-juices: 3.76 [95% CI: 1.13-15.18]; OR herbal tea: 2.91 [95% CI: 1.34-6.56]).
CONCLUSION
We suggest that more restrictive public health preventive recommendations should be made regarding the consumption of Annonaceae products. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 36210778
doi: 10.1002/mds.29222
pmc: PMC10092620
doi:
Substances chimiques
Teas, Herbal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2355-2366Informations de copyright
© 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Lancet. 1999 Jul 24;354(9175):281-6
pubmed: 10440304
Mov Disord. 2008 Aug 15;23(11):1546-50
pubmed: 18546326
Alzheimers Dement (N Y). 2020 Aug 27;6(1):e12074
pubmed: 32885026
Brain. 2008 Oct;131(Pt 10):2701-9
pubmed: 18941145
Mov Disord. 2004 May;19(5):603-4
pubmed: 15133832
J Neurochem. 2004 Jan;88(1):63-9
pubmed: 14675150
J Neurosci. 2007 Jul 18;27(29):7827-37
pubmed: 17634376
Food Chem. 2017 Jul 1;226:32-40
pubmed: 28254016
Neurology. 1988 Jun;38(6):900-3
pubmed: 3368071
Mov Disord. 2008 Nov 15;23(15):2122-8
pubmed: 18816693
Clin Neurophysiol. 2013 Nov;124(11):2216-29
pubmed: 23806744
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Brain. 2007 Mar;130(Pt 3):816-27
pubmed: 17303592
J Neurol Sci. 2018 May 15;388:220-221
pubmed: 29449009
Exp Neurol. 2014 Mar;253:113-25
pubmed: 24389273
Bone Marrow Transplant. 2020 Apr;55(4):675-680
pubmed: 31576022
Can J Neurol Sci. 1997 Feb;24(1):29-36
pubmed: 9043744
Mov Disord. 2008 Dec 15;23(16):2384-91
pubmed: 18785640
J Neurochem. 2016 Nov;139(4):624-639
pubmed: 27569447
Neurotoxicology. 2012 Jan;33(1):53-8
pubmed: 22130466
Nature. 2021 Nov;599(7886):650-656
pubmed: 34732887
Lancet Neurol. 2014 Jun;13(6):575-86
pubmed: 24703753
J Neurol Sci. 2018 May 15;388:214-219
pubmed: 29525296
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
Rev Neurol (Paris). 2000 May;156(5):459-72
pubmed: 10844366
J Mov Disord. 2016 Sep;9(3):152-9
pubmed: 27667187
Mov Disord. 2000 Jan;15(1):18-23
pubmed: 10634237
J Med Internet Res. 2018 Jul 09;20(7):e10493
pubmed: 29986849
Acta Neuropathol Commun. 2019 Feb 15;7(1):22
pubmed: 30767766
J Agric Food Chem. 2014 Aug 27;62(34):8696-704
pubmed: 25088119
Brain. 2010 Aug;133(Pt 8):2410-25
pubmed: 20826434
Life Sci. 2003 May 9;72(25):2853-61
pubmed: 12697268
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Neuroscience. 2003;121(2):287-96
pubmed: 14521988
J Commun Disord. 1997 Jan-Feb;30(1):11-21; quiz 21-2
pubmed: 9017475
Arch Neurol. 2004 Jul;61(7):1104-7
pubmed: 15262742
J Int Neuropsychol Soc. 2000 May;6(4):460-8
pubmed: 10902415
Sleep. 2007 Aug;30(8):1026-32
pubmed: 17702273
Sleep Med. 2015 Jan;16(1):186-9
pubmed: 25534709